(Press-News.org)
Researchers have used heart and lung stem cells infected with the virus that causes COVID-19 to better understand how the disease impacts different organs, paving the way for more targeted treatments.
The research, co-led by Murdoch Children’s Research Institute and the Peter Doherty Institute for Infection and Immunity (Doherty Institute), found the responses to SARS-CoV-2 varied significantly depending on the cell type, allowing the team to identify effective anti-viral drugs to treat infection in heart and lung cells. The findings were published in the 10th anniversary edition of Stem Cell Reports.
Murdoch Children’s Associate Professor David Elliott, also a principal investigator at The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), said discovering that COVID-19 triggered variable cellular responses in different organs would provide new insights into treatment strategies.
“To further our knowledge on the impact of SARS-CoV-2 on different organs, we engineered human stem cells in the lab into lung and heart cells and infected with them with the virus,” he said.
“We found the heart and lungs exhibit distinct antiviral and toxicity profiles that could inform better COVID-19 therapies and treat its complications.
“Our findings highlight the importance of using several cell types for the evaluation of antiviral drugs to determine the best drug combinations for effective treatment of a virus that affects multiple organ systems.”
The Royal Melbourne Hospital and University of Melbourne Professor Kanta Subbarao, Virologist and Director of the WHO Collaborating Centre for Reference and Research on Influenza at the Doherty Institute, said while SARS-CoV-2 primarily infected the respiratory tract, lung and cardiac complications occur in severe cases of COVID-19.
Cardiac complications are observed in up to 78 per cent of recovered COVID-19 patients and ongoing myocardial inflammation in 60 per cent of patients.
“Although COVID-19 vaccines are highly effective in preventing severe illness and death, antiviral compounds are required for the treatment of COVID-19, particularly with the emergence of variant viruses that evade immunity,” Professor Subbarao said.
“To date, only a handful of drugs have been approved for use in hospitalised COVID-19 patients and more are needed.”
The study also looked at approved drugs for treating COVID-19, including Remdesivir and Molnupiravir, with some found to be more effective than others at treating infection in lung and heart stem cells. It identified Alectinib and SPHINX31 as promising antivirals for SARS-CoV-2 in both heart and lung cells.
“We have provided valuable insights into virus-host interactions in tissues that are significantly affected in COVID-19, with implications that will further therapeutic options,” Professor Subbarao said.
Researchers from Monash University, The University of Sydney, The Walter and Eliza Hall Institute of Medical Research, the University of Melbourne and The Royal Children's Hospital also contributed to the findings.
Publication: Rajeev Rudraraju, Matthew J. Gartner, Jessica A. Neil, Elizabeth S. Stout, Joseph Chen, Elise J. Needham, Michael See, Charley Mackenzie-Kludas, Leo Yi Yang Lee, Mingyang Wang, Hayley Pointer, Kathy Karavendzas, Dad Abu-Bonsrah, Damien Drew, Yu Bo Yang Sun, Jia Ping Tan, Guizhi Sun, Abbas Salavaty, Natalie Charitakis, Hieu T. Nim, Peter D Currie, Wai-Hong Tham, Enzo Porrello, Jose M. Polo, Sean J. Humphrey, Mirana Ramialison, David A. Elliott and Kanta Subbarao, ‘Parallel use of human stem cell lung and heart models provide insights for SARSCoV-2 treatment,’ Stem Cell Reports. DOI: 10.1016/j.stemcr.2023.05.007
*The content of this communication is the sole responsibility of the Murdoch Children’s and does not reflect the views of the NHMRC.
Available for interview:
Dr Beth Stout, Murdoch Children’s Research Officer, Heart Disease
Dr Jessica Neil, Doherty Institute Research Officer
END
Four state policies introduced during the COVID-19 pandemic to spur expansion of telehealth were associated with expansion of such services by mental health facilities, but growth of telehealth was lower among facilities in counties with the greatest proportion of Black residents, according to a new RAND Corporation study.
Expansion of telehealth also was lower among facilities that accepted Medicaid or the Children’s Health Insurance Program, two government insurance programs that aid primarily lower-income Americans, according to the study.
The findings show that disparities in access to mental health care persisted even as ...
Only 1 in 4 residential addiction treatment facilities caring for U.S. adolescents under 18 years old offer buprenorphine, a medication used to treat opioid use disorder, according to a new study. Only 1 in 8 offer buprenorphine for ongoing treatment. These findings highlight a significant gap in access to evidence-based addiction treatment among young people. Published in JAMA, this study was supported by the National Institute on Drug Abuse (NIDA) and the National Center for Advancing Translational Sciences ...
LA JOLLA (June 13, 2023)—The immune system protects the body from invaders, such as bacteria, viruses, or tumors, with its intricate network of proteins, cells, and organs. Specialized immune cells, called cytotoxic T cells, can develop into short-lived effector cells that kill infected or cancerous cells within our bodies. A small portion of those effector cells remain after an infection and become longer-lived memory cells, which “remember” infections and respond when infections reappear. ...
PHILADELPHIA—The Pew Charitable Trusts today announced the 22 researchers selected to join the Pew Scholars Program in the Biomedical Sciences. These early-career scientists will receive four years of funding to spearhead innovative studies exploring human health and medicine.
“From vaccine development to treatments for complex diseases, biomedical research is foundational to solving some of the world’s greatest health challenges,” said Susan K. Urahn, Pew’s president and CEO. “Pew is thrilled to welcome this new class of researchers and support their efforts to advance scientific knowledge and improve human ...
PHILADEPHIA—The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2023 class of the Pew-Stewart Scholars Program for Cancer Research.
These early-career scientists will receive four-year grants to explore new horizons in cancer development, diagnosis, and treatment. This class marks the 10th year the Alexander and Margaret Stewart Trust has partnered with Pew to build a legacy of innovative cancer research.
“Cancer is one of the most pressing challenges facing biomedical researchers today,” said Susan K. Urahn, Pew’s president and CEO. “Pew ...
PHILADELPHIA – The Pew Charitable Trusts today announced the 2023 class members of the Pew Latin American Fellows Program in the Biomedical Sciences.
These 10 postdoctoral fellows from seven Latin American countries—Argentina, Brazil, Chile, Colombia, Mexico, Peru, and Uruguay—will receive two years of funding to conduct research in laboratories throughout the United States. The fellows will work under the mentorship of prominent biomedical scientists, including an alum of the Pew Scholars Program in the Biomedical Sciences.
“Scientific ...
Most women diagnosed with early stage breast cancer today can expect to become long term cancer survivors, finds a study published by The BMJ today.
The findings show that the average risk of dying from breast cancer in the five years after a diagnosis has fallen from 14% to 5% since the 1990s. For those diagnosed during 2010-15, more than six in 10 women had a five year risk of 3% or less.
The researchers say their findings can be used to reassure most women treated for early breast cancer that they are likely to become long term cancer survivors. ...
The American College of Medical Genetics and Genomics (ACMG) has released updated recommendations for CFTR carrier screening –Updated recommendations for CFTR carrier screening: A position statement of the American College of Medical Genetics and Genomics. Pathogenic variants in the CFTR gene can cause cystic fibrosis (CF) as well as CF-related disorders. The new updated ACMG CFTR variant list includes a set of 100 variants.*
The new CFTR variant list represents an updated minimum recommended variant set for CF carrier screening and supersedes the previous group of 23 CFTR variants recommended by the ACMG. These revised recommendations apply to carrier screening, a type of genetic ...
OAK BROOK, Ill. – A common weight-loss surgery for obese adolescents and young adults is found to have harmful effects on bones, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).
“Childhood obesity is on the rise and weight-loss surgery is the most effective way to reduce weight and improve cardiometabolic comorbidities,” said the study’s lead investigator, Miriam A. Bredella, M.D., professor of radiology at Harvard Medical School in Boston, Massachusetts, and vice chair for Faculty Affairs and Clinical Operations, Department of Radiology ...
PeerJ, the award-winning Open Access publisher, has announced the launch of the Open Advances series of journals, part of its ongoing commitment to democratizing scientific communication. The series will foster an equitable approach that empowers researchers worldwide to contribute valuable insights towards solving global challenges. The journals will be fully Open Access but will not charge authors a fee to publish.
The Open Advances series is a transformative endeavor that cements PeerJ's commitment to openness, innovation, ...
